- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating the Alzheimer Disease Blood Test Revolution
A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.
On this week’s episode of Managed Care Cast, we're discussing a significant advancement in health care: the May 16 FDA approval of the first blood test to diagnose Alzheimer disease. This landmark approval marks a shift in how Alzheimer disease is identified, moving away from more traditional methods, like brain scans, or invasive methods, like spinal taps.
The Lumipulse test from Fujirebio Diagnostics measures 2 proteins found in blood plasma, with their ratio helping physicians understand the risk of cognitive symptoms being caused by Alzheimer pathology. Our guests, Howard Fillit, MD, cofounder and chief science officer of the Alzheimer’s Drug Discovery Foundation, and Anthony “Nino” Sireci, MD, MSc, senior vice president, clinical biomarker and diagnostics development, Eli Lilly and Company, will help us understand what they call a “huge accomplishment.”
With validation data showing over 91% concordance with traditional amyloid plaque detection, the blood test is more affordable, less invasive, and more accessible, which could revolutionize diagnosis and treatment accessibility and transform the diagnostic landscape from one of helplessness to one of hope and early intervention.
Listen above or on one of these podcast services:
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
